NCT04081389 2023-09-11
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1 Completed
Clinical Trials
38 trialsNCT03599453 2023-07-18
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Completed
NCT00062010 2023-07-07
Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00679289 2022-10-12
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 2 Completed
NCT03403634 2022-03-02
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
Phase 2 Completed
NCT00398450 2021-03-03
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
University of California, San Diego
Phase 1 Completed
NCT02339324 2021-02-24
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
University of Pittsburgh
Phase 1 Completed
NCT03066947 2021-01-29
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
BriaCell Therapeutics Corporation
Phase 1/2 Completed
NCT00577993 2020-11-16
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00498979 2020-07-24
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Case Comprehensive Cancer Center
Phase 1 Completed
NCT02151448 2020-07-20
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
University of Pittsburgh
Phase 1/2 Completed
NCT02331706 2020-04-21
IFN-DLI for Relapsed Acute Leukemia After Allo-SCT
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed
NCT00004088 2019-07-02
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT01603212 2019-05-21
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01100528 2019-02-26
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00629200 2018-11-15
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00038376 2018-10-29
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01622933 2017-08-31
Multiple Antigen-Engineered DC Vaccine for Melanoma
University of Pittsburgh
Phase 1 Completed
NCT02199327 2017-08-08
Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
Coordinación de Investigación en Salud, Mexico
Phase 4 Completed
NCT00006244 2017-07-12
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00059826 2016-12-07
Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00548847 2016-10-26
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Emory University
Phase 2 Completed
NCT00126594 2016-09-16
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00445523 2016-03-17
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00083551 2015-11-23
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
University of Arkansas
Phase 3 Completed
NCT00375661 2015-09-02
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Kyoto University Hospital
Phase 4 Completed
NCT00082719 2015-05-14
Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00002621 2014-07-24
Interferon Alfa in Treating Children With HIV-Related Cancer
Children's Oncology Group
Phase 2 Completed
NCT01743157 2013-08-29
BBI
California Pacific Medical Center Research Institute
Phase 1/2 Completed
NCT00059813 2013-08-26
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00026143 2013-06-05
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002556 2013-05-31
Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00217542 2013-05-03
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT00101114 2013-02-28
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00970996 2013-01-03
BCAA
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00329368 2012-03-09
Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer
Endocyte
Phase 1 Completed
NCT00221702 2010-10-13
EADO
University Hospital, Bordeaux
Phase 3 Completed
NCT00273247 2006-01-09
Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
National Cancer Institute, Milan
Phase 3 Completed